Parkinson’s Disease Therapeutics Market Size - By Drug Class, By Route of Administration, By Patient, By Distribution Channel - Global Forecast, 2025 - 2034

Parkinson’s Disease Therapeutics Market Size

The global parkinson’s disease therapeutics market was valued at USD 6.2 billion in 2024 and is set to reach USD 13.3 billion by 2034, growing at a CAGR of 8.1% from 2025 to 2034. The market is witnessing rapid growth owing to the increasing prevalence of Parkinson's disease, especially in the aging population. As the global life expectancy rises, the prevalence of Parkinson's disease, which has a strong age correlation, will also rise. This trend is prominent in North America and Europe along with some countries in the Asia-Pacific region, where the population aged 65 and above is growing at a very high rate. The increase in the elderly population has broadened the patient pool and subsequently the demand for effective therapeutic options, making Parkinson's disease a primary concern for healthcare systems.
 

Further, the market is expected to grow with the expanding pipeline of therapeutics, such as gene therapies, neuroprotective agents, and stem cell-based therapies. For instance, in 2023, the National Institutes of Health (NIH) reported funding over USD 253 million to Parkinson's research, focusing on the development of novel therapeutics. The market expansion is fueled by this significant investment which not only enhances scientific discovery but also improves the entire pipeline.
 

Additionally, the expansion of the market has been aided by the advancements in therapeutic options. Although conventional treatments like levodopa/carbidopa remain the gold standard in PD management, emerging options like adenosine A2A antagonists and glutamate antagonists are gaining popularity due to their symptom relief and targeted treatment. Furthermore, innovations in drug delivery mechanisms, such as transdermal drug delivery systems including transdermal patches, inhalable formulations, and infusion therapies, are improving treatment efficacy and patient adherence. Together, these factors are expected to drive the growth of the Parkinson's disease therapeutics market in the near future.
 

Parkinson's disease therapeutics include drugs and treatments that manage the symptoms of Parkinson's disease, a chronic neurodegenerative disease disturbing movement and non-motor functions. Major therapies include dopaminergic drugs like levodopa, dopamine agonists, and MAO-B inhibitors, as well as adjunct treatments like COMT inhibitors and amantadine. The primary aim of these therapeutics is to manage or alleviate the symptoms and slow the progression of the disease.
 

Parkinson’s Disease Therapeutics Market Trends

• A key trend propelling the growth of the Parkinson's disease therapeutics market is the growing aging population coupled with increasing prevalence of Parkinson's disease in this demographic.
   
• According to the World Health Organization (WHO), the global count of people aged 60 years and older is projected to reach approximately 2.1 billion by 2050 from 1 billion in the year 2020. Parkinson's disease mainly affects those aged 60 and above, with the risk of developing the disease rising significantly with age.
   
• Thus, this high elderly population results in an escalated patient base, further raising the need for effective therapeutics that can assist in managing PD symptoms.
   
• Furthermore, the rising occurrence of PD significantly contributes to the growing demand. For instance, as per the Parkinson's Foundation estimates, nearly 10 million individuals are living with PD globally as of 2024. This growing number of patients affected by PD increases the demand for effective treatments, thereby fostering market growth.
   
• This trend has spurred pharmaceutical innovation, resulting in the creation of therapies like extended-release levodopa, infusion systems, and adenosine A2A antagonists.
   
• Moreover, there is a growing focus on developing therapies that modify the disease to effectively slow its progression, which is expected to further support the market growth.
   
• Thus, together the rising aging population and growing incidence of PD are key trends fueling market growth, as well as fostering the development of new and innovative treatments and therapies targeted towards previously unmet patient needs and enhancing patient outcomes.
   

Trump Administration Tariffs

• The tariffs introduced under the Trump administration might significantly affect the Parkinson's disease therapeutics market by potentially raising the cost and complicating the importation of active pharmaceutical ingredients (APIs), excipients, and finished drug products from China and other countries affected by the tariffs.
   
• Pharmaceutical companies that depend on international supply chains to manufacture dopamine agonists, MAO-B inhibitors, and other major Parkinson's medications might incur higher production costs. The major pharmaceutical companies including AstraZeneca, Sanofi, GSK, and Eli Lilly have manufacturing sites in the U.S. for products sold in China that could be caught in the tariff crossfire, with China recently raising its levies on U.S. imports to 125% in response to U.S. tariff increases.
   
• These potential cost increases might create a higher financial burden for patients, possibly putting pressure on insurance providers and public healthcare systems, especially in low-margin economies.
   
• Smaller biotech firms and specialty pharmaceutical companies lacking the financial cushioning of larger companies might find these additional costs more challenging to manage. This could potentially slow drug development pipelines or delay product launch dates for new Parkinson's treatments. There are several promising Parkinson's treatments in the pipeline, including Appello Pharmaceuticals' mGlu4 PAM AP-472, which began Phase 1 clinical trials in October 2021 and is designed to work in conjunction with levodopa.
   
• Trade regulation uncertainty might inhibit overseas investment and development of Parkinson's research and innovations. The North America dominated the Parkinson's disease treatment market with a 39.5% revenue share in 2024, this position could be affected by continued trade tensions. Regional market dynamics could shift as companies potentially reconsider their global research and manufacturing strategies.
   
• Tariff-induced shifts in the supply chain can also create temporary drug shortages or delays in the availability of certain products, thereby hampering patient care.
   
• In the long term, the Parkinson’s therapeutics landscape will have to pivot toward more domestic production or diversified global sourcing. However, the transitional obstacles will likely restrict access, affordability, and fresh ideas in the early stages.
   

Parkinson’s Disease Therapeutics Market Analysis

Based on the drug class, the global Parkinson’s disease therapeutics market is segmented into levodopa/carbidopa, dopamine agonists, adenosine A2A antagonists, COMT inhibitors, MAO-B inhibitors, glutamate antagonists, cholinesterase inhibitors, and other drug classes. The levodopa/carbidopa segment dominated the global market and was valued at USD 3 billion in 2024.
 

• High market share of this segment is due to the unparalleled effectiveness of treating symptoms including bradykinesia, tremors, and rigidity, thus making it the gold standard for Parkinson's disease treatment.
   
• Additionally, the innovations in formulations such as extended-release tablets and infusion systems which further enhance long-term symptom control and reduce motor fluctuations continue to sustain market dominance.
   
• Moreover, the low cost of levodopa/carbidopa and availability across regions, especially in low and middle-income countries, broadens the scope of its utilization in various patient demographics.
   

Based on the route of administration, the global Parkinson’s disease therapeutics market is categorized into oral, transdermal, subcutaneous, and other routes of administration. The oral segment dominated the market in 2024 with a market share of 63.3%.
 

• Oral formulations are easy to administer, thus making them a preferred choice by patients undergoing long-term treatment. This improves compliance, especially in chronic diseases such as PD, where patients often require lifelong treatment.
   
• Further, the majority of medications for relieving motor symptoms, such as levodopa/carbidopa and some dopamine agonists that are highly prescribed are mostly available in oral form; this further contributes to the segment's growth.
   
• Moreover, the economic advantage of oral drugs over other forms of treatment, such as intravenous or infusion therapies, has further strengthened their dominance, particularly in cost-sensitive regions.
   

Based on the patient, the global Parkinson’s disease therapeutics market is divided into adult and pediatric. The adult segment held highest market share in 2024 and is poised to witness about 8.2% CAGR through 2034.
 

• Adults, particularly aged 60 and above, are majorly affected by Parkinson's disease and the risk of developing the disease increases with age, which in turn supports the growth of the adult segment.
   
• Additionally, adult patients tend to suffer from more complicated symptoms and comorbidities, requiring specialized care and customized treatment plans. Thus, this age group benefits from treatments that manage both the motor and non-motor symptoms of PD, such as cognitive decline and mood disorders.
   
• Furthermore, the improved awareness of PD among healthcare providers has shifted attention towards early diagnosis, resulting in enhanced identification and treatment initiation among older patients, thereby aiding in market growth.
   

Based on the distribution channel, the global Parkinson’s disease therapeutics market is classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment accounted for over 45.1% of market share in 2024.
 

• Hospital pharmacies offer access to a broader variety of therapies, including infusion therapies, advanced formulations, and other forms of combination therapy.
   
• Additionally, hospital pharmacies play a vital role in the management of acute motor fluctuations and cognitive decline PD complications, where immediate and expert care is necessary.
   
• Further, the credibility and dependability of hospital pharmacies also supports their dominance, since patients prefer to obtain prescriptions in hospital settings, where they can receive specialized attention and professional guidance.
   
• Moreover, hospitals along with multidisciplinary teams are pivotal in managing complicated cases, thus further solidifying the market share of hospital pharmacies.
   

The North America Parkinson’s disease therapeutics market dominated with a share of 39.5% in 2024.
 

The U.S. market for Parkinson’s disease therapeutics was valued at USD 2 billion in 2021. In 2024, the U.S. dominated the North America market with a revenue of USD 2.3 billion, growing from USD 2.2 billion in 2023 and USD 2.1 billion in 2022.
 

• The U.S. maintains a leading market share in the Parkinson's disease therapeutics market owing to the presence of an advanced healthcare system in the country, leading pharmaceutical firms, and early adoption of innovative treatments.
   
• In addition, strong regulatory policy enables the timely approval of new drugs and therapies using fast-track and breakthrough designations.
   
• Furthermore, several government and non-government initiatives to support PD patients drive the adoption of treatment. For example, the PD GENEration initiative by the Parkinson's Foundation offers complimentary counseling as well as genetic testing for up to 15,000 people diagnosed with Parkinson's disease in the U.S., aiding in identifying relevant genetic mutations.
   
• Such initiatives are extremely valuable in fast-tracking the enrollment of patients into clinical trials and subsequently advancing the research and development in PD treatment and care. The increased participation in clinical trials boosts the demand for new therapies, thus contributing to market growth.
   

Germany is expected to experience significant growth in the Europe Parkinson’s disease therapeutics market.
 

• Germany holds a strong position in the Europe Parkinson's disease therapeutics market owing to its advanced healthcare system, strong pharmaceutical sector, and the growing prevalence of neurodegenerative disorders within its older population.
   
• According to the National Institutes of Health, in 2022, in Germany, there were 18.6 million individuals aged 65 and above, which includes 6.1 million who are aged 80 and above. As this demographic is more susceptible to Parkinson's disease, there is an increased demand for Parkinson's disease treatments in Germany.
   
• Further, the country's healthcare system provides coverage for Parkinson's disease management, which includes dopamine agonists, MAO-B inhibitors, and levodopa.
   
• Additionally, Germany has a presence of prominent pharmaceutical companies and research institutions that play a significant role in medical research and innovation, which foster advancements in the Parkinson's disease therapeutics market in the country.
   

India Parkinson’s disease therapeutics market in is forecasted to grow substantially during the forecast period.
 

• The improvements in healthcare infrastructure and access to advanced treatments in India are contributing to market growth.
   
• Further, the rising healthcare expenditure and the availability of affordable treatments compared to Western markets make Parkinson's disease therapies more accessible to a broader population.
   
• These factors combined are expected to drive significant growth in the Parkinson's disease therapeutics market in India.
   

Brazil is anticipated to witness considerable growth in the Latin America Parkinson’s disease therapeutics market throughout the analysis period.
 

• The rising demand for affordable therapies and the presence of global pharmaceutical companies in Brazil are boosting the availability of cost-effective treatments, supporting the market's expansion.
   
• Additionally, efforts by the government to improve healthcare access, along with a focus on innovative treatments and clinical trials, are also expected to contribute to market growth over the analysis period.
   

The Saudi Arabia Parkinson’s disease therapeutics market in is set for high growth in the Middle East and Africa market.
 

• According to data published in the National Institutes of Health, a community survey conducted in Saudi Arabia estimated the prevalence of Parkinson's Disease (PD) to be 27 per 100,000 population, indicating a significant need for therapeutic solutions as the disease continues to affect more individuals.
   
• Additionally, Saudi Arabia has a growing aging population, with an increasing number of elderly individuals who are at higher risk for PD. This demographic shift is expected to further elevate the demand for Parkinson's disease treatments in the country.
   

Parkinson’s Disease Therapeutics Market Share

Parkinson’s disease therapeutics industry is relatively consolidated, with key pharmaceutical and biotech firms leading the space, while early-stage innovation remains active among smaller companies. Major market players are employing strategic initiatives such as partnerships, acquisitions, product innovation, and geographic expansion to strengthen their market positions and stay ahead of the competition. The top 5 players in the Parkinson’s therapeutics segment including F. Hoffmann-La Roche, Kyowa Kirin, Acadia Pharmaceuticals, UCB, and AbbVie accounted for approximately 40% of market share. These industry leaders focus on advancing novel treatments and optimizing existing therapies to improve patient outcomes.
 

Parkinson’s Disease Therapeutics Market Companies

Few of the prominent players operating in the Parkinson’s disease therapeutics industry include:

• AbbVie
• Acadia Pharmaceuticals
• Acorda Therapeutics (Merz Therapeutics)
• Amneal Pharmaceuticals
• Boehringer Ingelheim
• Desitin Arzneimittel
• F. Hoffmann-La Roche
• Kyowa Kirin
• Newron Pharmaceuticals
• Novartis
• Orion Pharma
• Sumitomo Dainippon Pharma
• Supernus Pharmaceuticals
• Teva Pharmaceutical
• UCB
   

AbbVie entered the Parkinson's disease therapeutics market with a series of product launches and targeted acquisitions aimed at enhancing its neurology portfolio. In October 2024, AbbVie introduced Vyalev for advanced Parkinson's disease, offering a 24-hour subcutaneous levodopa-based infusion as an alternative to oral medications and surgical interventions. Similarly, in January 2024, the company launched Produodopa to manage motor fluctuations in patients unresponsive to standard treatments. Both launches were backed by robust clinical data and have contributed to reshaping treatment in advanced stages of Parkinson's disease.
 

Acadia Pharmaceuticals has established a focused presence in the Parkinson's disease therapeutics market by focusing on the neuropsychiatric aspects of the disease, particularly Parkinson's disease psychosis (PDP). Its lead product, NUPLAZID (pimavanserin), is the first FDA-approved treatment specifically for hallucinations and delusions in PDP, addressing a significant unmet need in this patient population. Beyond this, Acadia is advancing novel treatments for treatment-induced psychosis through clinical trials, demonstrating promising results in Phase II studies.
 

Parkinson’s Disease Therapeutics Industry News

• In September 2024, Amneal Pharmaceuticals announced the launch of CREXONT (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson's disease. This helped the company to tap into the growing Parkinson's disease therapeutics market and boost revenue growth.
   
• In July 2024, Merz Therapeutics acquired Inbrija from Acorda Therapeutics, strengthening its neurology portfolio. The acquisition helped Acorda to reduce its operational costs and refocus resources on its core business areas.
   
• In June 2024, Orion signed a license and supply agreement with Navamedic for Flexilev, a treatment for advanced Parkinson's disease. Orion marketed the drug in 27 European countries, while Navamedic managed manufacturing and supply. The deal included upfront and milestone payments, expanding Orion's neurology portfolio.
   
• In January 2024, AbbVie announced the launch of PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease with severe motor fluctuations, hyperkinesia (excessive movement), or dyskinesia (involuntary movement). This helped the company to strengthen its product portfolio and generate revenue.
   

The Parkinson’s disease therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Levodopa/carbidopa
• Dopamine agonists
• Adenosine A2A antagonists
• COMT inhibitors
• MAO-B inhibitors
• Glutamate antagonists
• Cholinesterase inhibitors
• Other drug classes

Market, By Route of Administration

• Oral
• Transdermal
• Subcutaneous
• Other routes of administration

Market, By Patient

• Adult
• Pediatric

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE